Add BrightSurf on Google Email

Loss of gene promotes brain-tumor development, reduces survival, study finds

A recent study published in the New England Journal of Medicine found that losing the NFKBIA gene promotes glioblastoma multiforme growth and reduces survival. Restoring this gene may improve survival for certain patients with glioblastoma, as it inhibits tumor cell growth and increases sensitivity to chemotherapy.

SourceOhio State University Wexner Medical Center·JournalNew England Journal of Medicine·DateJan 6, 2011

Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting

Phase III trial data suggests Tumor Treating Fields (TTF) therapy increases median survival time and improves quality of life scores compared to standard chemotherapy. Younger patients and those with better functional status show an impressive survival advantage.

JCI table of contents: Feb. 22, 2010

Researchers at Stanford University School of Medicine have found that disrupting the SDF-1/CXCR4 interaction can prevent the recruitment of vasculogenic cells to the tumor site, blocking postirradiation development of functional tumor vasculature and tumor regrowth. This approach may be applicable to treating glioblastoma multiforme.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateFeb 22, 2010

Addition of chemotherapy to radiotherapy continues to increase survival in patients with brain tumors for up to 5 years

The EORTC-NCIC trial found that adding chemotherapy to radiotherapy significantly increases survival in glioblastoma patients, with improved outcomes seen across all clinical prognostic subgroups. The study suggests testing tumour MGMT gene methylation status to identify patients most likely to benefit from this treatment.

SourceThe Lancet_DELETED·JournalThe Lancet Oncology·DateMar 8, 2009

Brain tumors: New therapy surprisingly successful

Researchers at Bonn University discovered a critical improvement in treating glioblastoma, the most aggressive and common brain tumor. The combination of two drugs increased average survival time to 23 months, with some patients surviving over four years. Further investigations are needed to optimize this therapy.

SourceUniversity of Bonn·JournalJournal of Clinical Oncology·DateMar 6, 2009

JCI online early table of contents: Aug. 1, 2008

Researchers have discovered a mechanism to overcome the resistance of human glioblastoma multiforme cells to growth factor inhibitors by blocking inhibitor of apoptosis proteins. Combining drugs targeting IAPs with RTK inhibitors showed enhanced efficacy in inhibiting tumor growth. Additionally, targeting liver CB1 receptors may provid...

SourceJCI Journals·JournalJournal of Clinical Investigation·DateAug 1, 2008

Gene therapy 'trains' immune system to destroy brain cancer cells and reverses behavioral deficits

Researchers developed gene therapy approach that attracts and 'trains' immune system cells to destroy deadly brain cancer cells, promoting long-term immunity and restoring normal brain function. The therapy shows promise as a potential treatment for glioblastoma multiforme, the most common and deadly type of brain cancer.

SourceCedars-Sinai Medical Center·JournalMolecular Therapy·DateFeb 19, 2008

Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors

A study published in the Journal of Neurosurgery found that simultaneous implantation of radioactive seeds and chemotherapy wafers following surgery improved patient survival rates for recurrent glioblastoma multiforme (GBM) patients. The median survival was 69 weeks, with nearly a quarter of patients surviving two years.

SourceUniversity of Cincinnati·JournalJournal of Neurosurgery·DateJan 18, 2008